Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L, Balachandran A, Larkin R, Seneviratne JA, Chung SA, Lalwani A, Tsubota S, Beck D, Kadomatsu K, Beckers A, Durink K, De Preter K, Speleman F, Haber M, Norris MD, Swarbrick A, Cheung BB, Marshall GM, Carter DR.
Zhai L, et al. Among authors: haber m.
Int J Mol Sci. 2023 Oct 25;24(21):15571. doi: 10.3390/ijms242115571.
Int J Mol Sci. 2023.
PMID: 37958555
Free PMC article.